Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropeginterferon alfa-2b vs PEG-Intron in chronic HCV genotype 2
CTR20190555Phase 3Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of ropeginterferon alfa-2b in chronic hepatitis C (CHC), sponsored by Hansoh Pharmaceutical Group. Started Apr 2019; status: completed.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on CTR20190555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190555.